Leerink Partnrs Comments on Nkarta FY2024 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Nkarta in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch expects that the company will post earnings per share of ($1.77) for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Nkarta’s Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($1.86) EPS.

Several other analysts also recently issued reports on NKTX. Mizuho decreased their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Needham & Company LLC reduced their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, HC Wainwright dropped their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Nkarta has a consensus rating of “Buy” and a consensus price target of $15.00.

Nkarta Stock Up 4.2 %

NASDAQ NKTX opened at $2.21 on Monday. The stock’s 50-day moving average price is $2.35 and its 200-day moving average price is $3.59. Nkarta has a 52 week low of $1.96 and a 52 week high of $16.24. The company has a market capitalization of $155.96 million, a P/E ratio of -1.18 and a beta of 0.85.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares in the company, valued at $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Nkarta

A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its holdings in Nkarta by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 31,056 shares of the company’s stock valued at $77,000 after acquiring an additional 6,763 shares during the period. Catalina Capital Group LLC lifted its holdings in shares of Nkarta by 57.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock worth $47,000 after buying an additional 6,867 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock worth $60,000 after buying an additional 7,030 shares during the period. Erste Asset Management GmbH purchased a new stake in shares of Nkarta in the 3rd quarter worth $33,000. Finally, American Century Companies Inc. lifted its holdings in shares of Nkarta by 8.8% in the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock worth $226,000 after buying an additional 7,378 shares during the period. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.